Literature DB >> 3033547

Dexamethasone suppression test abnormalities in multiple sclerosis: relation to ACTH therapy.

A T Reder, M T Lowy, H Y Meltzer, J P Antel.   

Abstract

We studied the 1-mg overnight dexamethasone suppression test (DST) in patients with MS. In about 50% of patients, serum cortisol did not fall below 5.0 micrograms/dl. This percentage was similar in patients with major depression, but contrasted to 11% in normal controls. MS nonsuppressors were not more depressed than suppressors; dexamethasone bioavailability may have contributed because nonsuppressors had lower serum dexamethasone levels than suppressors. Suppressors improved in the week following ACTH therapy; nonsuppressors did not. Furthermore, serum dexamethasone values correlated positively with clinical response to ACTH treatment. The DST may be a useful neuroendocrine test of glucocorticoid sensitivity in MS patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033547     DOI: 10.1212/wnl.37.5.849

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

Review 1.  Neurovascular glucocorticoid receptors and glucocorticoids: implications in health, neurological disorders and drug therapy.

Authors:  Sherice Williams; Chaitali Ghosh
Journal:  Drug Discov Today       Date:  2019-09-18       Impact factor: 7.851

2.  An analysis of peripheral type benzodiazepine receptors on blood mononuclear cells during high dose steroid treatment of multiple sclerosis.

Authors:  P Ferrero; P Rocca; P Benna; C De Leo; E Montalenti; L Ravizza; B Bergamasco
Journal:  Ital J Neurol Sci       Date:  1992-11

3.  Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis.

Authors:  Linda Rolf; Jan Damoiseaux; Inge Huitinga; Dorien Kimenai; Jody van den Ouweland; Raymond Hupperts; Joost Smolders
Journal:  Front Neurol       Date:  2018-04-26       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.